Loading clinical trials...
Loading clinical trials...
A Multicenter Phase II Trial of Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Conditions
Interventions
IBI308
Bevacizumab
+3 more
Locations
1
China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Start Date
March 1, 2019
Primary Completion Date
December 31, 2029
Completion Date
December 31, 2029
Last Updated
April 21, 2026
NCT05692635
NCT07250477
NCT06943820
NCT05713006
NCT06111807
NCT05557552
Lead Sponsor
Sun Yat-sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions